Followers | 130 |
Posts | 5096 |
Boards Moderated | 6 |
Alias Born | 04/12/2010 |
Thursday, October 01, 2020 12:14:53 PM
Investors were rightfully disappointed that PRO2TECT missed on the safety endpoint, as the NDD patient pool is much, much larger than the DD patient pool. Still, our model shows that even just assuming a reasonable market share for DD patients alone (in the US and EU) is enough to qualify this stock as a buy (keep in mind that vadadustat has already been approved and launched in Japan for both DD and NDD indications).
One of our favorite types of stocks to look for is one that has been oversold based on fear. We think AKBA fits the bill. Competitor FGEN actually finished down 7% on the day after being up 15% premarket on the AKBA trial failure news. Granted, the market was down about 3% on September 3. But if AKBA's trial failure truly meant that it was out of the competition for the multi-billion dollar market that is anemia due to CKD, then we think FGEN's stock would have reacted positively and been able to sustain its gain.
Instead, we think that AKBA was overly punished, and that the drop in its share price was more severe than the actual news. For this reason, we think the drop was an overreaction and that the stock is mispriced.
https://seekingalpha.com/article/4374119-akebia-therapeutics-drop-from-missed-safety-endpoint-offers-good-reentry-point
PLEASE CHECK OUT MY BOARD- http://investorshub.advfn.com/JER1%e2%80%99s-Investment-Trading-&-News-Chat-21922/
Recent AKBA News
- Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights • PR Newswire (US) • 05/02/2024 12:30:00 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 05/01/2024 08:05:00 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 04/02/2024 08:05:00 PM
- Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis • PR Newswire (US) • 03/28/2024 12:26:00 AM
- Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights • PR Newswire (US) • 03/14/2024 08:15:00 PM
- Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results • PR Newswire (US) • 03/11/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:49:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:48:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:47:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:46:51 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 03/01/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:03:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:02:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:01:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:00:49 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/29/2024 09:32:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/29/2024 09:28:33 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/29/2024 09:27:09 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/27/2024 11:19:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/27/2024 11:14:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/27/2024 11:11:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:11:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:11:44 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM